| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B | 24.54B |
| Cost of revenue | 11.05B | 8.42B | 7.08B | 6.63B | 7.31B | 5.48B |
| Gross profit | 54.13B | 36.63B | 27.04B | 21.91B | 21.01B | 19.06B |
| Research and development | 13.34B | 10.99B | 9.31B | 7.19B | 6.93B | 5.98B |
| Selling, general and admin | 11.09B | 8.59B | 7.40B | 6.44B | 6.43B | 6.12B |
| Interest expense | 895.00M | 781.00M | 485.90M | 331.60M | 339.80M | 359.60M |
| Income before tax | 25.73B | 12.68B | 6.55B | 6.81B | 6.16B | 7.23B |
| Income tax | 5.09B | 2.09B | 1.31B | 561.60M | 573.80M | 1.04B |
| Net income | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B |
| EPS | 23.00 | 11.76 | 5.82 | 6.93 | 6.15 | 6.82 |
| EPS (diluted) | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 |
| Diluted shares | 899.30M | 904.10M | 903.30M | 904.62M | 911.68M | 912.50M |
| Dividends per share | 6.23 | 5.40 | 4.69 | 4.07 | 3.53 | 3.07 |
From Eli Lilly's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.